Prevalence and impact of baseline NSA resistance associated variants (RAVs) on the efficacy of elbasvir/grazoprevir (EBR/GZR) against GT1a infection [abstract LB-22] | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Prevalence and impact of baseline NSA resistance associated variants (RAVs) on the efficacy of elbasvir/grazoprevir (EBR/GZR) against GT1a infection [abstract LB-22]

Jacobson IM, Asante-Appiah E, Wong P, Black T, Howe A, Wahl J, et al. Prevalence and impact of baseline NSA resistance associated variants (RAVs) on the efficacy of elbasvir/grazoprevir (EBR/GZR) against GT1a infection [abstract LB-22]. The Liver Meeting. San Francisco, CA; 2015.

Publication Type:

Conference Proceedings

Authors:

Ira M. Jacobson; Asante-Appiah, E.; Wong, P.; Black, T.; Howe, A.; Wahl, J.; Robertson, M.N.; Nguyen, B-Y.; Shaughnessy, M.; Hwang, P.; Barr, E.; Hazuda, D.

Source:

The Liver Meeting, San Francisco, CA (2015)

Abstract:

LB-22

Cited On:

Export Citation:

RIS Format

Top